Abivax S.A. — Investor Relations & Filings
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core strategy revolves around modulating the immune response through microRNA (miRNA). Its lead drug candidate, obefazimod, is an investigational, orally administered small molecule with a novel mechanism of action. Obefazimod is designed to enhance the expression of miR-124, a key microRNA that regulates the inflammatory response. The primary development goal is the commercialization of obefazimod for the treatment of ulcerative colitis, with clinical programs also underway for Crohn's disease. The company is exploring obefazimod for other inflammatory indications and is investigating follow-on compounds from its proprietary chemical library.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| 6-K - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| SCHEDULE 13G/A Filing | 2026-02-13 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 43481539 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 43132807 | 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 33016665 | S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016505 | 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016424 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 32249312 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 13630008 | Major Shareholding Notification 2026 | 2026-01-14 | English | ||
| 13630005 | Regulatory Filings 2026 | 2026-01-08 | English | ||
|
2025
7 filings
| |||||
| 13630007 | 6-K | 2025-12-15 | English | ||
| 13630010 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630009 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630012 | Major Shareholding Notification 2025 | 2025-10-30 | English | ||
| 13630011 | Regulatory Filings 2025 | 2025-10-28 | English | ||
| 13630013 | 6-K | 2025-09-08 | English | ||
| 13630014 | Major Shareholding Notification 2025 | 2025-08-14 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Apeloa Pharmaceutical Co.,Ltd.
Integrated provider of APIs, CDMO services, and finished dr…
|
000739 | CN | Manufacturing |
|
ApicHope Pharmaceutical Group Co.,Ltd
Pharmaceutical firm focused on pediatric, chronic, and card…
|
300723 | CN | Manufacturing |
|
Apimeds Pharmaceuticals US, Inc.
Clinical-stage biopharma developing a bee venom drug and AI…
|
APUS | US | Manufacturing |
|
Apogee Therapeutics, Inc.
Clinical-stage biotech developing biologics for immunologic…
|
APGE | US | Manufacturing |
|
Apollomics Inc.
Clinical-stage biotech developing innovative oncology and c…
|
APLM | US | Manufacturing |
|
Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single P…
|
APPH | DE | Manufacturing |
|
Appili Therapeutics Inc.
Biopharmaceutical company developing novel medicines for in…
|
APLI | CA | Manufacturing |
|
Applied BioCode Corporation
Develops and manufactures high-throughput multiplex molecul…
|
6598 | TW | Manufacturing |
|
Applied Therapeutics, Inc.
Clinical-stage biopharma developing novel drugs for rare me…
|
APLT | US | Manufacturing |
|
Aprogen Biologics Inc.
Develops and manufactures novel biologics and biosimilar an…
|
003060 | KR | Manufacturing |
Abivax S.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30868/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30868 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30868 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30868 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30868}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abivax S.A. (id: 30868)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.